MOLECULAR TEMPLATES INC (MTEM)
US6085502085 - Common Stock
Stay updated with the stocks that are on the move in today's after-hours session.
Discover the top movers in Thursday's after-hours session and stay informed about the post-market dynamics.
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Which stocks are experiencing notable movement on Thursday?
These stocks are making the most noise in today's session. Stay tuned for the latest updates!
Let's have a look at what is happening on the US markets on Thursday. Below you can find the most active stocks in today's session.
Which stocks are moving on Thursday?
Let's have a look at the top gainers and losers in the middle of the day of today's session.
MTEM Stock Earnings: Molecular Templates Beats EPS, Beats Revenue for Q2 2024
MTEM stock results show that Molecular Templates beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
MTEM Stock Earnings: Molecular Templates Beats EPS, Beats Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Molecular Templates (NASDAQ:MTEM) just reported results for the second quarter ...
Molecular Templates, Inc. Reports Second Quarter 2024 Financial Results and Corporate Update
Monotherapy activity of long duration in patients who have progressed on checkpoint therapy via a novel immuno-oncology mechanism of action with PD-L1 ETB...
7 F-Rated Penny Stocks to Avoid This June
These F-rated penny stocks have the lowest ratings from the Portfolio Grader based on factors like earnings, growth and momentum.
Molecular Templates, Inc. Provides Interim Update
Continued monotherapy activity in solid tumors with MT-6402 (PD-L1-targeting ETB) in checkpoint-experienced patients.Early pre-clinical and clinical data...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time to dive into the biggest pre-market stock movers for Thursday as we check out all of the hottest news this morning!
MTEM Stock Earnings: Molecular Templates Beats EPS, Beats Revenue for Q1 2024
MTEM stock results show that Molecular Templates beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
MTEM Stock Earnings: Molecular Templates Beats EPS, Beats Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Molecular Templates (NASDAQ:MTEM) just reported results for the first quarter o...
Molecular Templates, Inc. Reports First Quarter 2024 Financial Results and Corporate Update
AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage...
MTEM Stock Earnings: Molecular Templates Beats EPS, Misses Revenue for Q4 2023
MTEM stock results show that Molecular Templates beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.
MTEM Stock Earnings: Molecular Templates Beats EPS, Misses Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Molecular Templates (NASDAQ:MTEM) just reported results for the fourth quarter ...
Molecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting; Monotherapy Activity in Checkpoint-Experienced Head and Neck Cancer
AUSTIN, Texas, April 09, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage...
Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update
AUSTIN, Texas, March 29, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage...
Molecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase Agreement
AUSTIN, Texas, March 28, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage...
Molecular Templates, Inc. Provides Interim Update
Monotherapy activity with PD-L1-targeting MT-6402 in Head and Neck Cancer; Unique pharmacodynamic effects with CTLA-4 targeting MT-8421 in on-going phase I...